Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Steris

This article was originally published in The Gray Sheet

Executive Summary

Allows $110 mil. acquisition offer for U.K.-based Isotron plc to lapse, citing the lack of that firm's shareholder acceptance of the deal, Steris says Aug. 12. First announced July 20, the deal was intended to give Steris a foothold for expansion into the European market (1"The Gray Sheet" July 26, p. 9). Isotron is a provider of sterilization services for single-use medical products. Conditioned on a minimum of 90% Isotron shareholder acceptance of the deal, Steris had received only 60.4% of shareholder acceptances by the Aug. 11 due date. Steris concluded it was "not in the best interests of its shareholders to continue with the offer"

You may also be interested in...



Steris' Isotron Acquisition Adds European Contract Sterilization Services

The purchase of contract sterilization and related services firm Isotron gives Steris a foothold in the European market on which to further expand throughout the continent. Announced July 20, the cash deal is valued at $110 mil.

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel